Pentixapharm Holding AG Stock
Price
Target price
€2.44
€2.44
2.490%
0.06
2.490%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Pentixapharm Holding
sharewise wants to provide you with the best news and tools for Pentixapharm Holding, so we directly link to the best financial data sources.
Financials
News
![EQS-News: [68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market](https://www.sharewise.com/assets/news/news2-43a650f8b830e72801e4feae71d912bbee126d79fc8a8386e39fa6ba5787dbcb.png)
EQS-News: [68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
EQS-News: [68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market
EQS-News: Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
EQS-News: Pentixapharm Announces FDA Clearance of IND for Phase 3 PANDA Study of First-in-Class Cardiovascular Diagnostic Program
EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review
EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review
EQS-News: Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
EQS-News: Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
EQS-News: Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum
EQS-News: Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum
EQS-News: Pentixapharm Holding AG Appoints Erik Merten to the Executive Board
EQS-News: Pentixapharm Holding AG Appoints Erik Merten to the Executive Board
EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
EQS-News: Pentixapharm Holding AG will publish its financial report for the 2025 fiscal year on March 26, 2026
EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
EQS-News: Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
EQS-News: Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
EQS-News: Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension